Home » Latest News » Business » CrossChem’s 2025 Turnover Reaches €18.8M with 33% EBITDA Growth

CrossChem’s 2025 Turnover Reaches €18.8M with 33% EBITDA Growth

0 comments

Latvian chemical product manufacturer SIA “CrossChem” reported unaudited revenue of €18.8 million in 2025, alongside a 33% increase in EBITDA compared to the previous year, reaching nearly €1.4 million. The results demonstrate consistent growth and continued strategic investment in the company’s development.

The company expanded its client portfolio by 4%, increased the volume of laboratory analyses by 26%, and introduced several new products for both professional and household segments. This growth reflects a broader trend of increasing demand for specialized chemical products in the Baltic region.

In 2025, CrossChem invested approximately €1.5 million in research, modernization of production, and process automation, strengthening the company’s efficiency and long-term competitiveness.

The company slightly exceeded its key management guideline of an EBITDA margin of 6-7% – achieving 7.3%, despite some fluctuations in revenue due to the international nature of the industry. This performance confirms a stable return and the company’s ability to meet its obligations while ensuring further growth.

Article continues after advertisement

“CrossChem consistently implements a long-term development strategy, focusing on the development of chemical product circulation infrastructure, expansion of the product portfolio, and expansion of sales markets. Investments in technology and the team allow us to build a sustainable growth model,” said Richard Anderson, Chairman of the Board of CrossChem.

The company plans to achieve a turnover of €20-25 million in 2026, maintaining an EBITDA margin within the 6-7% range.

External financing is secured through bonds (in the form of guaranteed securities) listed on the Nasdaq Riga First North alternative market, as well as bank loans. CrossChem carefully monitors interest rate fluctuations, particularly EURIBOR, systematically manages debtor receivables, and reinsures risks with international insurance companies.

CrossChem continues to focus on increasing efficiency, modernizing work processes and automation, investing in infrastructure, equipment and team development to target stable and sustainable growth.

Related articles

Investor Andris earns 10% per year lending to Baltic companies through Capitalia
While the primary focus of investor Andris’ investment portfolio is on stocks and index funds, one of Andris’ portfolio investments is also in corporate lending platform Capitalia. This investment has quietly, but consistently and passively earned 10% per year, proving that disciplined investment in small and medium-sized enterprise (SME) loans in the Baltics can generate stable returns that significantly exceed the indicators of our region’s bond market. This is a brief overview of how investor Andris has performed with investments in the Capitalia platform.
0 FacebookTwitterPinterestEmail

Bio: Michael Brown is the Business Editor at Headlinez.News, specializing in financial markets, economic policy, and corporate developments. A seasoned business journalist with more than 14 years in the field, Michael has covered Wall Street, global trade, and the evolving tech-economy interface. His data-driven approach and accessible analysis help readers understand complex economic issues with clarity and depth. Expertise: Financial markets, economic poli

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy